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Abstract A high-yield production of a peptide vaccine in
transgenic plants is described here. A 21-mer peptide, which
confers protection to dogs against challenge with virulent canine
parvovirus, has been expressed in transgenic plants as an amino-
terminal translational fusion with the GUS gene. Transformants
were selected on the basis of their GUS activities, showing
expression levels of the recombinant protein up to 3% of the total
leaf soluble protein, a production yield comparable to that
obtained with the same epitope expressed by chimeric plant
viruses. The immunogenicity of the plant-derived peptide was
demonstrated in mice immunized either intraperitoneally or
orally with transgenic plant extracts, providing the suitability of
the GUS fusions approach for low-cost production of peptide
vaccines. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Subunit vaccines have improved conventional attenuated or
killed vaccines in many aspects including safety and produc-
tion systems. However, production of recombinant vaccine
proteins in expression systems is expensive, requiring large
scale fermenters and stringent puri¢cation protocols. These
fermentation processes for vaccine production may be a pro-
hibitively expensive technology for developing countries or for
application in animal health. The expression of foreign pro-
teins in plants has become an attractive alternative to conven-
tional production systems as they allow to obtain recombinant
proteins in large quantities at low cost. Plant-made vaccines
or antibodies are specially attractive as plants are free of hu-
man or animal diseases, reducing screening costs for viruses
and bacterial toxins. Proteins produced in transgenic plants
are capable of invoking protective immune responses against
important pathogens as it has already been demonstrated
[1^9]. In addition, plants enable oral delivery of vaccine anti-
gens eliminating the injection-related manipulations of ani-
mals or hazards in humans. At present, vaccines for human
and animal disease prevention comprise the most competitive
area for plant-based production of xenogenic proteins [10].
One of the major disadvantages of using transgenic plants
as bioreactors to produce vaccines is the expression levels and
accumulation in plant tissues of the recombinant vaccine pro-
teins. In contrast, chimeric plant viruses expressing peptides
or complete proteins from pathogens are very e⁄ciently accu-
mulating the xenogenic proteins in plants [10]. Nevertheless,
the production of vaccine antigens by genetically manipulated
viruses requires an extra step of inoculation of the host plant
with the chimeric virus and could present additional risks
derived from the spread of recombinant viruses to the envi-
ronment.
In the present work, we have assayed an alternative to
produce high levels of a vaccine peptide fused to L-glucuro-
nidase (GUS) protein, which shows a reduced turnover and
additionally enables the rapid screening of high level expres-
sion transformants. We selected a linear antigenic peptide de-
rived from the VP2 capsid protein of canine parvovirus
(CPV). This 21-mer peptide has been shown to be e¡ective
in protection of dogs and minks against parvovirus infection
[11,12]. In this report, we demonstrate that this peptide, fused
to the GUS protein, was e⁄ciently expressed and accumulated
in transgenic plants, at similar levels obtained with recombi-
nant plant viruses [13,14].
2. Materials and methods
2.1. Construction of plasmid, plant transformation and analysis of
GUS activity
The DNA sequence corresponding to 2L21 epitope was obtained by
a PCR-based gene assembly by overlap extension using the following
oligonucleotides: (A) 5P-GCGCGGATCCATGTCTGATGGAGCT-
GTTCAACCAGATGGTGGTCAACCTG-3P and (B) 5P-GCGCG-
GATCCTCCAGTAGCTCTCTGTTTCTAACAGCAGGTTGACC-
ACCA-3P. Sequence of primers was adapted to the most frequent
codon usage in Arabidopsis [15] as it is shown in Fig. 1A. An extra
ATG was added to the 5P end of 2L21 DNA to introduce an initiation
codon. The annealed oligomers were cloned into the BamHI site of
the plasmid pUC19 and then digested with XbaI and SmaI for sub-
cloning the 2L21 encoding DNA fragment into the binary plasmid
pBI121 (Clontech, Palo Alto, CA, USA). The resulting plasmid,
named pBI-2L21, contained the 2L21 encoding region fused in-frame
to the 5P end of the GUS gene under the control of the cauli£ower
mosaic virus 35S (CaMV 35S) promoter.
Arabidopsis plant transformation was carried out as described else-
where [16] with slight modi¢cations [7]. T1 plants were analyzed for
the presence of the foreign DNA sequence by PCR using primers for
ampli¢cation of a fragment of 1 kb from 2L21-GUS fusion gene as
described [7]. Selected T1 plants were self-pollinated to obtain T2 and
T3 generations. GUS activities were determined in plant tissues ac-
cording to the method of Je¡erson et al. [17].
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2.2. Analysis of expression of 2L21-GUS fusion protein in transformed
plants
Plant soluble proteins were obtained by homogenization of leaves in
a blender with liquid nitrogen, and the resulting powder was resus-
pended in bu¡er (0.3 g of fresh weight/ml) containing 10 mM 2-(N-
morpholino)ethanesulfonic acid, pH 6, 10 mM NaCl, 5 mM EDTA,
0.6% Triton X-100, 0.25 M sucrose, 0.15 mM spermine, 0.5 mM
spermidine, 10 mM dithiothreitol, and 1 mM phenylmethylsulfonyl
£uoride. The extract was ¢ltered and centrifuged 10 min at
12 000Ug. Plant extracts were resolved in 15% sodium dodecyl sulfate
(SDS)^PAGE and transferred to nitrocellulose ¢lters. The presence of
2L21-GUS protein was detected in Western blot using monoclonal
antibody (MAb) 3C9 (Ingenasa, Madrid, Spain; [18]) at 0.1 Wg/ml
dilution and an anti-mouse IgG conjugated with alkaline phosphatase
(Roche Diagnostics, Germany). Reactions were developed with nitro-
blue tetrazolium chloride (Gibco-BRL Life Technology, Rockville,
MD, USA) and bromochloroindoyl phosphate (Pierce Chemical
Company, Rockford, USA). Intensity of MAb 3C9-reacting bands
in Western blots of known concentrations of baculovirus-expressed
CPV VP2 was compared in multiple reactions to that of 2L21-GUS
protein contained in di¡erent concentrations of total soluble protein
from leaf extracts. Quanti¢cation of reacting signals was carried out
by using Howteck Scanmaster 3+ scanner and Bioimage 3.3 software
(Millipore, USA). The average integrated densitometry values were
calculated for every transgenic plant in at least three independent
analyses.
2.3. Immunization of animals
Adult BALB/c mice divided in two di¡erent groups of 10 mice each
were immunized intraperitoneally on days 0, 15 and 30 with leaf
extracts from the highest 2L21-GUS expressing plant in complete
Freund’s adjuvant for the ¢rst inoculation and in incomplete adjuvant
for the others. One group received 100 Wg (low-dose experiment) and
the other 1.2 mg (high-dose experiment) of leaf soluble proteins, con-
taining 3.3 and 39.6 Wg of recombinant 2L21-GUS fusion protein,
respectively. A third group of 10 mice was immunized by oral gavage
with leaf proteins extracted in 5 mM sodium phosphate bu¡er (pH
7.2). Doses of 200 Wg of total soluble protein from leaf extracts were
administered to mice three times per week and during 4 alternative
weeks. Control mice were immunized by using the same protocols
with extracts from transgenic plants transformed with plasmid
pBI121. 15 days after the last immunization dose, mice were bled
and the antibody reactivity against 2L21 peptide was analyzed.
2.4. Determination of speci¢c antibodies in immunized mice
Baculovirus-expressed CPV VP2 forming virus-like particles (VLPs,
[19]) was used as antigen source for determination of 2L21-speci¢c
antibodies. Di¡erent concentrations (0.2^4 Wg) of VLPs puri¢ed as
described previously [20] were resolved in a 9% SDS^PAGE and
transferred to a Hybond-C membrane (Amersham Pharmacia Biotech
Europe, Germany) for Western blot analyses of sera from the respec-
tive 2L21-GUS-immunized mice diluted 1/100.
Titration of speci¢c antibodies from immunized mice by enzyme-
linked immunosorbent assay (ELISA) was carried out by two indirect
ELISAs. Peptide 2L21 coupled to keyhole limpet hemocyanin (KLH)
or puri¢ed VLPs were used as coating antigens. Polystyrene microtiter
plates (Labsystem, Finland) were coated overnight at 4‡C with the
peptide or VLPs at 5 Wg/ml diluted in 50 mM carbonate bu¡er, pH 9.6
and then serial 2-fold dilutions of the respective mouse antiserum were
added. After a 1 h incubation at 37‡C, peroxidase-labeled anti-mouse
IgG (Pierce Chemical Company, Rockford, USA) was added to each
well and was incubated 1 h at room temperature. Bound enzyme was
detected by adding ABTS (2,2P-azino-di[ethyl-benzothiazoline-sulfonic
acid]) (Sigma-Aldrich Quimica, Madrid, Spain) as substrate and
stopped after 10 min with 2% SDS. The optical density of samples
was determined at 405 nm using an ELISA reader (Bio-Tek Instru-
ments). ELISA titers were determined as log2 reciprocal serum dilu-
tion where absorbance amounted to three times the blank (preimmu-
nization serum).
The induction of antibodies to GUS protein in immunized mice was
determined by Western blot using 2.5 Wg per strip of GUS from Es-
cherichia coli (Boehringer Mannheim, Germany). Sera belonging to
every group of immunized mice were pooled and reacted in Western
blot at 1/100 dilution. For positive control of reaction an anti-GUS
rabbit IgG (2 mg/ml) was used (Molecular Probes, Leiden, The Neth-
erlands). A preimmune serum was used as negative control.
3. Results
3.1. Construction of 2L21-GUS fusion protein expression
vector
To examine the GUS fusion approach in plants, we used a
DNA encoding 21 amino acids corresponding to peptide
2L21, obtained by a PCR-based gene assembly, to construct
the pBI-2L21 expression vector. The peptide encoding se-
quence was mutagenized for optimizing the codon usage in
Arabidopsis and cloned in-frame to 5P end of the GUS report-
er gene in the plasmid pBI121, a diagram of which appears in
Fig. 1. The recombinant pBI-2L21 plasmid enables selection
of transformants on media containing kanamycin and stable
integration into nuclear chromosomal plant DNA. This plas-
mid uses the CaMV 35S promoter to drive nominally consti-
tutive transcription of the cloned gene.
3.2. Expression of 2L21-GUS fusion protein in transgenic
plants
Transformation of Arabidopsis plants with pBI-2L21 was
carried out by Agrobacterium tumefaciens in¢ltration. Twenty
¢ve independent kanamycin-resistant transgenic lines were ob-
tained appearing similar in morphology to wild-type plants.
All lines were positive when screened for the presence of the
recombinant genes by PCR analysis (not shown). The di¡er-
ent levels of GUS activity showed by independent transform-
ants are illustrated in Fig. 2A. As expected, when fully ex-
panded upper leaves from those plants were analyzed in
Western blot with MAb 3C9 against 2L21 peptide, a 73 kDa
immunoreactive band was detected in most plants, corre-
sponding to the 2L21-GUS fusion protein (Fig. 2B). No im-
munoreactive bands could be detected in leaf extracts from
plants transformed with pBI121 plasmid or in plants showing
low levels of GUS activity. A good correlation between GUS
Fig. 1. Schematic structure of the binary plasmid pBI-2L21 used for
Agrobacterium-mediated plant transformation. A represents the se-
quence of two overlapping oligonucleotides used for the synthesis of
the DNA fragment encoding the peptide 2L21 by recombinant
PCR. Nucleotides in bold represent the initiation codon and the en-
coding 2L21 region. Modi¢cations introduced in the sequence of
these oligonucleotides to optimize the most common codon usage in
Arabidopsis are represented in italics. B represents the resulting plas-
mid pBI-2L21 after cloning of 2L21 encoding sequence downstream
of the CaMV 355 promoter in plasmid pBI121. The amino acid se-
quence of 2L21 peptide derived from the nucleotide sequence repre-
sented in A is also shown.
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Fig. 2. Characterization of transgenic plants obtained with plasmid pBI-2L21. A represents the levels of GUS activity in transgenic T2 lines
transformed with plasmid pBI121 (1) or pBI-2L21 (2^13). GUS activity of leaves in individual transgenic lines was determined and shown as
produced amount of 4-methylumbelliferone per min per mg soluble leaf protein at 37‡C. Bars represent the mean of GUS activity and standard
deviation of di¡erent leaves from the same plant. B shows the expression of 2L21-GUS protein in leaves from the same plants, detected by
Western blot using 30 Wg of soluble leaf proteins and MAb 3C9. C represents the quanti¢cation of 2L21 peptide production by comparative in-
tegrated densitometry values obtained from Western blot reactions using MAb 3C9. This panel shows reactivity with the MAb of di¡erent
known amounts of recombinant CPV VP2 (0.2^4 Wg) and the recombinant 2L21 peptide contained in di¡erent amounts of soluble leaf proteins
(5^30 Wg) from several homozygous transgenic plants (1, 4, 6 and 12). The calculated percentage of recombinant fusion protein production in
plants is also indicated.
Fig. 3. Antibody responses to the plant-derived 2L21 peptide and GUS protein in immunized mice. Reactivity in Western blot against recombi-
nant CPV VP2 of sera from mice immunized intraperitoneally with low (A) or high (B) antigen doses and orally (C). MAb 3C9 was used as
positive control of reactions (C) and a pool of sera from mice immunized with plant extracts transformed with plasmid pBI121 was used as
negative control (C3). D shows the reactivity in Western blot against GUS protein of pools of sera from mice immunized intraperitoneally
(low and high doses) and orally. A speci¢c serum against GUS (2 mg/ml) was used as positive control and a preimmune serum was used as
negative control. E represents the mean ELISA titers and standard deviations of sera from the di¡erent groups of immunized mice compared
to those obtained with MAb 3C9. The MAb was used in ELISA and Western blot at a 0.1 Wg/ml concentration.
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activity and reactivity of fusion protein in Western blot was
observed. Homozygous plants from lines showing the highest
GUS activity were isolated and used in further experiments.
They showed an increase of about 20% of GUS activity with
respect to their parental T2 segregating transgenic lines.
Quanti¢cation of 2L21-GUS fusion protein in leaves from
transgenic plants using MAb 3C9 rendered percentages of
2L21-GUS protein accumulation in the highest expressing
plants between 0.15 and 3.3% of total soluble leaf protein.
This represents yields of 2L21-GUS protein production of
about 75 Wg/g of fresh weight of transgenic plant leaves.
Fig. 2C shows a representative reactivity of MAb 3C9 in
Western blot of di¡erent concentrations of recombinant
CPV VP2 compared to that obtained from di¡erent leaf ex-
tracts. These results were con¢rmed analyzing the extinction
signal of reacting bands with MAb 3C9 in Western blot of
serial dilutions of known amounts of CPV VP2, a synthetic
2L21 peptide coupled to KLH protein and leaf extracts (not
shown). As expected from using the CaMV 35S promoter,
recombinant protein was histochemically detected by GUS
expression in all plant tissues (not shown).
3.3. Antibody response to plant-derived 2L21 peptide
To test the ability to stimulate production of CPV-speci¢c
antibodies, several amounts of transgenic plant extracts ex-
pressing 2L21-GUS fusion protein were used intraperitoneally
or orally to immunize mice. All mice belonging to the parent-
erally immunized groups developed speci¢c antibodies against
2L21 peptide that reacted in Western blot with the baculovi-
rus-expressed CPV VP2 (Fig. 3A,B). The antibody response
was quanti¢ed by ELISA using recombinant CPV VLPs (Fig.
3D) or a synthetic 2L21 peptide coupled to KLH protein (not
shown), showing similar results. The speci¢c antibody titers
were proportional to the amount of recombinant fusion pro-
tein used in the immunization protocol, reaching ELISA titers
of 12 for the peptide or CPV VLPs when mice were immu-
nized with 1.2 mg of plant extract. Interestingly, most mice
(nine out of 10) immunized orally with leaf soluble proteins
from transgenic plants developed speci¢c antibodies against
2L21 peptide detectable in Western blot and ELISA (Fig.
3C,D). Speci¢c antibodies against GUS protein were also de-
tected in immunized mice by Western blot (Fig. 3E), indicat-
ing that, as expected, the immune response was not exclusively
restricted to the 2L21 peptide.
4. Discussion
Two major prerequisites for application of transgenic plant-
derived vaccines to human or animal health have to be ad-
dressed. First is to determine the dosage, best delivery method
and immune response type obtained with the plant-derived
vaccine. Information about these aspects has been acquired
with several infectious models such as Vibrio cholerae [6], HIV
[21], Pseudomonas aeruginosa [22], murine hepatitis virus [23],
foot and mouth disease virus [4,5], transmissible gastroenter-
itis virus [7,8] or E. coli heat labile enterotoxin [24,25] among
others. Nevertheless, current information is still insu⁄cient to
generalize procedures for every vaccine antigen obtained in
transgenic plants. Second is the ever-present mission of in-
creasing the level of transgene expression within transgenic
plants. While several opportunities exist to increase expres-
sion, which ones are likely to produce the best e¡ect need
to be determined on a case by case basis. For vaccine produc-
tion in transgenic plants, a reduced number of alternatives to
increase recombinant protein accumulation have been as-
sayed. Good results were obtained by the use of endoplasmic
reticulum retention signals [6,26], increasing the translational
e⁄ciency of RNAs with 5P untranslated region from tobacco
etch virus [2] or using a plant-optimizing synthetic gene [24].
At present, expression levels of vaccine proteins higher than
0.4% of soluble plant protein have not been reported [2] and
in most cases expression levels of vaccine proteins in trans-
genic plants were lower than 0.1%.
Additionally to the above mentioned low expression levels
of vaccine proteins found in plants, instability of short pep-
tides in plant cells could also make di⁄cult the production of
peptide vaccines in transgenic plants. In the present work an
approach has been assayed to increase a vaccine peptide ex-
pression, the 2L21 peptide from CPV, as a fusion protein with
GUS, a reporter protein commonly used in plant molecular
biology because of its optimal expression and accumulation.
The selection of 2L21 peptide to be expressed by this strategy
is because it constitutes an example of an e⁄cient peptide
vaccine [11]. Previously, this peptide was successfully ex-
pressed in two plant viruses, the cowpea mosaic virus [13]
and the plum pox potyvirus [14]. This feature allows to com-
pare the expression levels obtained by using transgenic plants
versus those obtained by recombinant plant viruses. Here, we
have demonstrated that expression of 2L21 peptide as a trans-
lational fusion protein with GUS compares favorably with
expression levels of the same peptide obtained by recombinant
plant viruses. To our knowledge, this is the ¢rst description of
stable expression of a viral peptide in transgenic plants, open-
ing the possibility of a low-cost alternative for producing pep-
tide vaccines. Additionally, GUS fusion proteins provide a
simple system for screening a high number of transgenic
plants to select those with higher levels of peptide accumula-
tion.
In general, peptides themselves evoke poor immune re-
sponses in immunized animals. In previous experiments
[11,26], humoral or cellular immune responses against 2L21
peptide were detectable only when animals were immunized
with the peptide coupled to KLH protein but not with the free
peptide. Protein KLH not only serves as a carrier for the
correct presentation of the peptide to the immune system,
but also because it contains T-cell epitopes which potentiate
the immune response against to the coupled peptide. In fact,
all protective results obtained with peptide 2L21 in target
animals were only obtained when animals received high doses
of the peptide coupled to KLH protein. GUS protein seems
not negatively a¡ecting the immune response obtained in im-
munized mice against the 2L21 peptide, which was immuno-
genic by the intraperitoneal and oral route. However, the anti-
body immune response we obtained with the fusion protein
was lower than using the same peptide coupled to KLH pro-
tein, suggesting that GUS protein does not act as a similarly
e⁄cient immunological carrier.
How the fusion of peptides to GUS protein may facilitate
the recombinant protein accumulation in transgenic plants
requires further investigation. Apparently, in plants trans-
formed for expressing the GUS fusion, the speci¢c mRNA
levels, examined by Northern blot analysis using a 2L21 en-
coding DNA fragment as the hybridization probe, showed a
good correlation with the GUS activity and protein accumu-
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lation detected in the di¡erent plants (not shown). GUS fu-
sions also could eliminate ine⁄cient processing or premature
degradation of the peptide, allowing accumulation of the fu-
sion protein at levels up to 3% of total soluble protein. We
have successfully expressed other short amino acid sequences
from foot and mouth disease virus and bovine rotavirus in
plants fused to GUS protein (unpublished results), suggesting
that this methodology is applicable to any peptide of interest.
The possibility to increase large vaccine proteins accumulation
by translational fusions to GUS is currently under investiga-
tion.
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